Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 4/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7301332 | 0.89 | THRB (0.50) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL698742 | 0.89 | KDM4E (0.61) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL3723645 | 0.86 | KDM4E (0.58) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL789770 | 0.81 | KMT2A (0.41) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| Urea SCHEMBL10485832 | 0.80 | KDM4E (0.42) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL29633266 | 0.80 | ALDH1A1 (0.63) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL10924109 | 0.80 | THRB (0.43) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL9109 | 0.80 | ALDH1A1 (0.63) | KDM4EALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL31676719 | 0.79 | KDM4E (0.56) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL3456805 | 0.79 | KDM4E (0.56) | KDM4EALDH1A1MAPTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1354740-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-06-19 | — | — | CN | claimed |
| CN-119930459-A | Preparation method of 5-bromoacetyl salicylamide | 杭州盛弗泰新材料科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119857095-A | Choroidal neovascularization inhibitor or drusen inhibitor and its evaluation or screening method | 林科杰诺米克斯股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119095569-A | Powder for use in treating tooth surfaces | 福尔顿控股公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-118164871-A | N-ester-2-acetylsalicylamide compound and preparation method and application thereof | 湖南科技大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-118001260-A | Dissolving monosodium urate for treating gout | 贺亮 | 2024-05-10 | — | — | CN | disclosed |
| CN-115996686-B | Medical device comprising expandable muscle polymer | 巴德外周血管股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-110582286-B | Ocular application of matrix-bound vesicles (MBVs) | 联邦高等教育系统匹兹堡大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-111491625-B | Dissolving monosodium urate for treating gout | 贺亮 | 2023-12-01 | — | — | CN | disclosed |
| CN-110658337-B | Diagnosis and treatment of autoimmune diseases | 武田药品工业株式会社 | 2023-06-16 | — | — | CN | disclosed |
| WO-2012092364-A2 | METHOD FOR SYMPATHETIC REBALANCING OF PATIENT | G & L CONSULTING, LLC (US) | 2012-07-05 | — | — | WO | disclosed |
| US-20120172680-A1 | METHOD FOR SYMPATHETIC REBALANCING OF PATIENT | G & L CONSULTING, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | The Government of the United States of America, as represented by the Secretary of | 2011-10-06 | — | — | US | disclosed |
| CN-101386581-B | Method for preparing acetsalicylamide | UNIV JIANGSU | 2011-07-06 | — | — | CN | disclosed |
| US-7973057-B2 | Thalidomide analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-07-05 | — | — | US | disclosed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | disclosed |
| CN-1354740-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-06-19 | — | — | CN | disclosed |
| US-4310521-A | ANALGESICS, ANTIPYRETICS AND ANTIINFLAMMATORY AGENTS | TOHO PHARMACEUTICAL CO., LTD. (JP) | 1982-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211728-A1 | Thalidomide analogs | TNF, TNFRSF1A, PGF | KDM4E 3440/4885ALDH1A1 336/4885MAPT 1972/4885 |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, PGF | KDM4E 3440/4885ALDH1A1 336/4885MAPT 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.